Changes in prostate-specific antigen kinetics during androgen-deprivation therapy as a predictor of response to abiraterone in chemonaïve patients with metastatic castration-resistant prostate cancer

Changes in prostate-specific antigen kinetics during androgen-deprivation therapy as a predictor of response to abiraterone in chemonaïve patients with metastatic castration-resistant prostate cancer

Purpose: Metastatic castration-resistant prostate cancer (mCRPC) has a poor prognosis. Abiraterone acetate (AA), enzalutamide, and chemotherapy are first-line treatments for patients with mCRPC. This study examined prognostic factors for AA response in the form of prostate-specific antigen (PSA) kin...

Full description

Bibliographic Details
Main Authors: Chung-Lin Lee, Ying-Hsu Chang, Chung-Yi Liu, Ming-Li Hsieh, Liang-Kang Huang, Yuan-Cheng Chu, Hung-Cheng Kan, Po-Hung Lin, Kai-Jie Yu, Cheng-Keng Chuang, Chun-Te Wu, See-Tong Pang, I-Hung Shao
Format: Article
Language:English
Published: Korean Urological Association 2022-09-01
Series:Investigative and Clinical Urology
Subjects:
nonsteroidal anti-androgens
prognosis
prostate-specific antigen
prostatic neoplasms
Online Access:https://www.icurology.org/pdf/10.4111/icu.20210450

Internet

https://www.icurology.org/pdf/10.4111/icu.20210450

Similar Items